Child Neurologist and Senior Clinician Scientist, Holland Bloorview Kids Rehabilitation Hospital
Associate Professor, Department of Pediatrics, University of Toronto
On September 26, 2018, Evdokia Anagnostou discussed the challenge of rethinking classification systems and diagnostic labels for autism and related neurodevelopmental disorders in light of recent findings from research and clinical studies.
On April 10, 2018, Matthew State reviewed the progress that has been made in autism genetics over the past 10 years and the role that the Simons Simplex Collection (SSC) played in this (r)evolution. He also addressed the potential contribution of ongoing genomic studies including whole-genome sequencing as well as the challenges and opportunities of leveraging the genetic findings to identify pathophysiological mechanisms.
Director, Developmental Neurophysiology Lab, Center for Autism Research and Treatment, University of California, Los Angeles
On 7 February 2018, Shafali Spurling Jeste provided a topical overview of the current state of research in autism biomarkers. She shared data from studies of autism biomarkers in three key areas: early risk prediction (studies of high-risk infants), heterogeneity within the autism spectrum and genetically defined subgroups within autism. Finally, she discussed the challenges around clinical trial design and development and considered how more objective measures of brain function can improve clinical trials.
Arousal, emotion regulation and challenging behaviors: Insights from the Autism Inpatient Collection
Vice President, Medical Affairs, Developmental Disorders Service, Maine Behavioral Healthcare
On 24 January 2018, Matthew Siegel drew upon a new resource, the Autism Inpatient Collection data set, to offer preliminary insights into the relationships between physiologic arousal, emotion dysregulation and the occurrence of challenging behaviors. Such behaviors may represent an attempt to modulate physiologic arousal in minimally verbal individuals with autism spectrum disorders.
On 28 November 2017, Daniel Geschwind discussed his group’s use of RNA sequencing, chromatin structure and gene networks to help develop an understanding of potential convergent mechanisms in autism spectrum disorders.
Join the SFARI science team and leaders in the autism research community for an informal evening of food, drink, conversation and mingling on 13 November 2017 in Washington, D.C.